Nivolumab & Ipilimumab

DRUG5 trials

Sponsors

University College, London, Vivace Therapeutics, Inc, The First Affiliated Hospital of Guangzhou Medical University, Guliz Ozgun, Inge Marie Svane

Conditions

Advanced Kidney CancerLung Cancer - Non Small CellMesotheliomaNSCLCProstate CancerSolid Tumor, AdultUveal Melanoma

Phase 1

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

RecruitingNCT04665206

Vivace Therapeutics, IncMesothelioma, NSCLC, Solid Tumor, Adult

Start: 2021-03-24End: 2030-03-02Target: 434Updated: 2026-04-02

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Not yet recruitingNCT07501117

Inge Marie SvaneUveal Melanoma

Start: 2026-05-01End: 2029-04-01Target: 15Updated: 2026-03-30

Phase 2

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Active, not recruitingNCT03061539

University College, LondonProstate Cancer

Start: 2018-02-06End: 2027-06-30Updated: 2022-09-28

Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

RecruitingNCT06926790

The First Affiliated Hospital of Guangzhou Medical UniversityLung Cancer - Non Small Cell

Start: 2025-02-17End: 2030-10-31Target: 69Updated: 2025-04-22

Phase 3

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

Not yet recruitingNCT07338981

Guliz OzgunAdvanced Kidney Cancer

Start: 2026-04-30End: 2032-12-31Target: 142Updated: 2026-01-14

Related Papers

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.

2025-10-197 citations

Abstract 4728: The selective Yap/Tead inhibitor TY-1054 re-sensitizes acquired resistance to multiple tyrosine kinase-based targeted therapies

Cancer Research2025-04-21

Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.

Journal of Clinical Oncology2024-06-017 citations

Abstract LB033: Identification of small molecule Pan-TEAD inhibitors disrupting YAP-TEAD protein-protein interaction and targeting gastric cancer cells

Cancer Research2024-04-051 citations

Abstract 4491: TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects <i>in vitro</i> and <i>in vivo</i>

Cancer Research2023-04-043 citations

Randomised phase II trial of stereotactic body radiotherapy in combination with<b>check</b>point inhibitors in metastatic castration-resistant<b>pro</b>state cancer (CheckPRO): a study protocol

BMJ Open2023-01-013 citations

Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).

Journal of Clinical Oncology2019-05-206 citations

Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.

2017-10-0149 citations